Related Experiment Video
Updated: Feb 3, 2026

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
Published on: February 19, 2021
Drug updates and approvals: 2018 in review
Cortney Mospan1, Geoffrey Mospan, Emily Byland
1Cortney Mospan is an assistant professor of pharmacy at Wingate University, Levine College of Health Sciences, Wingate, N.C. Geoffrey Mospan is an assistant professor of pharmacy at Wingate University, Levine College of Health Sciences, Wingate, N.C. Emily Byland is a PharmD candidate at Wingate University, School of Pharmacy, Wingate, N.C. William Blake Whitaker is a PharmD candidate at Wingate University, School of Pharmacy, Hendersonville, N.C. Linda Xiong is a PharmD candidate at Wingate University, School of Pharmacy, Wingate, N.C. Jordan Dunlap is a PharmD candidate at Wingate University, School of Pharmacy, Wingate, N.C. Katherine Canupp is a PharmD candidate at Wingate University, School of Pharmacy, Wingate, N.C.
Abstract:
In 2018, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy); doxylamine succinate and pyridoxine hydrochloride (Bonjesta); erenumab-aooe (Aimovig); lofexidine hydrochloride (Lucemyra); tezacaftor and ivacaftor (Symdeko); and tildrakizumab-asmn (Ilumya).
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Pharmacokinetics: Drug–Drug Interactions
Bioequivalence of Drugs: Drugs with Multiple Indications
Factors Influencing Drug Absorption: Drug Dissolution

